文献速递腹部介入CT

经导管动脉化疗栓塞联合酪氨酸激酶抑制剂治疗肝细胞癌患者的生存预测模型开发与验证

Development and validation of survival prediction models for patients with hepatocellular carcinoma treated with transcatheter arterial chemoembolization plus tyrosine kinase inhibitors.
PubMed 文献 · Radiol Med · 2024-10-14

研究纳入两个队列共111例接受经导管动脉化疗栓塞联合酪氨酸激酶抑制剂治疗的肝细胞癌患者,训练队列78例、测试队列33例,整合临床影像学特征、17条癌症相关信号通路突变负荷及CT影像组学评分构建列线图模型预测总生存期和无进展生存期,模型在训练与测试队列中C指数分别为0.805和0.768(OS)、0.782和0.766(PFS),校准与决策曲线分析支持其准确性和临床潜力。

要点

  • 联合模型预测OS纳入ECOG体能状态、Child-Pugh分级、瘤周强化、PI3K_AKT与缺氧突变负荷及影像组学评分。
  • 预测OS的1年、2年、3年AUC分别为0.889、0.900、0.917,训练队列C指数0.805、测试队列0.768。
  • 预测PFS纳入甲胎蛋白水平、肿瘤强化模式、缺氧与受体酪氨酸激酶突变负荷及影像组学评分,6个月和12个月AUC分别为0.885和0.925。

核心结论

  • 列线图模型有望预测接受经导管动脉化疗栓塞联合酪氨酸激酶抑制剂治疗的中晚期肝细胞癌患者的总生存期和无进展生存期,为治疗决策和病情监测提供有前景的工具。

研究设计与样本

  • 研究论文;两个队列共111例肝细胞癌患者用于构建预后模型,训练队列78例、测试队列33例;突变负荷基于17条癌症相关信号通路计算;影像组学特征从CT图像提取并采用pyradiomics系统筛选。

关键影像表现/征象

  • 瘤周强化被纳入预测总生存期的联合模型。
  • 肿瘤强化模式被纳入预测无进展生存期的联合模型。

诊断标准与关键数值

  • 预测总生存期的联合模型纳入ECOG体能状态、Child-Pugh分级、瘤周强化、PI3K_AKT与缺氧突变负荷及影像组学评分,训练队列C指数0.805、测试队列0.768。
  • 预测总生存期的1年、2年、3年AUC分别为0.889、0.900、0.917。
  • 预测无进展生存期的联合模型纳入甲胎蛋白水平、肿瘤强化模式、缺氧与受体酪氨酸激酶突变负荷及影像组学评分,训练队列C指数0.782、测试队列0.766。
  • 预测无进展生存期的6个月和12个月AUC分别为0.885和0.925。

临床应用与阅片要点

  • 原文结论认为列线图模型有望预测接受经导管动脉化疗栓塞联合酪氨酸激酶抑制剂治疗的中晚期肝细胞癌患者的总生存期和无进展生存期,为治疗决策和病情监测提供有前景的工具。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

英文原文(摘要)· 点击展开

BACKGROUND: Due to heterogeneity of molecular biology and microenvironment, therapeutic efficacy varies among hepatocellular carcinoma (HCC) patients treated with transcatheter arterial chemoembolization (TACE) and tyrosine kinase inhibitors (TKIs). We examined combined models using clinicoradiological characteristics, mutational burden of signaling pathways, and radiomics features to predict survival prognosis.

METHODS: Two cohorts comprising 111 patients with HCC were used to build prognostic models. The training and test cohorts included 78 and 33 individuals, respectively. Mutational burden was calculated based on 17 cancer-associated signaling pathways. Radiomic features were extracted and selected from computed tomography images using a pyradiomics system. Models based on clinicoradiological indicators, mutational burden, and radiomics score (rad-score) were built to predict overall survival (OS) and progression-free survival (PFS).

RESULTS: Eastern Cooperative Oncology Group performance status, Child-Pugh class, peritumoral enhancement, PI3K_AKT and hypoxia mutational burden, and rad-score were used to create a combined model predicting OS. C-indices were 0.805 (training cohort) and 0.768 (test cohort). The areas under the curve (AUCs) were 0.889, 0.900, and 0.917 for 1-year, 2-year, and 3-year OS, respectively. To predict PFS, alpha-fetoprotein level, tumor enhancement pattern, hypoxia and receptor tyrosine kinase mutational burden, and rad-score were used. C-indices were 0.782 (training cohort) and 0.766 (test cohort). AUCs were 0.885 and 0.925 for 6-month and 12-month PFS, respectively. Calibration and decision curve analyses supported the model's accuracy and clinical potential.

CONCLUSIONS: The nomogram models are hopeful to predict OS and PFS in patients with intermediate-advanced HCC treated with TACE plus TKIs, offering a promising tool for treatment decisions and monitoring patient progress.

来源:Radiol Med,查看原文。版权归原作者所有。

引用

  1. Huang K, Liu H, Wu Y, et al. Development and validation of survival prediction models for patients with hepatocellular carcinoma treated with transcatheter arterial chemoembolization plus tyrosine kinase inhibitors. Radiol Med. 2024. PMID: 39400683. doi:10.1007/s11547-024-01890-z

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。